LIB Therapeutics' Lerodalcibep Abstracts to be Presented at 92nd European Atherosclerosis Society Congress

LIB Therapeutics Inc., a privately-owned biopharmaceutical company, has made significant strides with its novel, third-generation PCSK9 inhibitor, Lerodalcibep. The company recently announced the acceptance of two abstracts from its Phase 3 LIBerate program for presentation at the upcoming 92nd European Atherosclerosis Society Congress, scheduled to take place in Lyon, France, from May 26-29, 2024.

The first presentation will be part of the "Science at a Glance Session - Late-Breaking Lipids" and is titled “Randomized, Open-Label, Study Comparing Efficacy and Safety of Lerodalcibep to Inclisiran in Patients with CVD or at High Risk for CVD Requiring Additional LDL-Cholesterol Reduction.” It is slated for May 28, between 1:30 PM and 1:37 PM CET, and will be presented by Prof. Ulrich Laufs of Germany. This study highlights the comparative effectiveness and safety of Lerodalcibep against Inclisiran in patients either suffering from cardiovascular disease (CVD) or those at elevated risk requiring further LDL-cholesterol reduction.

The second presentation, part of the "Late Breaker Session 2 - New therapeutic agents," will be held in René Leriche Hall - Forum 2. It is titled “Long Term Efficacy and Safety of Lerodalcibep in Patients with Atherosclerotic Cardiovascular Disease (LIBerate-CVD)” and will be presented by Dr. Evan Stein on May 29, from 11:00 AM to 11:15 AM CET. This session will focus on the prolonged efficacy and safety of Lerodalcibep in patients with atherosclerotic cardiovascular disease.

Lerodalcibep is a potent, small binding protein that functions as a third-generation PCSK9 inhibitor. Developed for convenient, once-monthly subcutaneous injections, it offers long-term ambient stability. Clinical trials have shown that Lerodalcibep can significantly reduce LDL-C levels, making it a promising treatment option for millions worldwide who suffer from atherosclerotic cardiovascular disease (ASCVD) and those at high risk, including approximately 30 million individuals with familial hypercholesterolemia (FH).

The global Phase 3 LIBerate program enrolled over 2,700 diverse participants, including those with CVD and individuals at very high and high risk for CVD, as well as patients with heterozygous and homozygous familial hypercholesterolemia. Lerodalcibep was administered monthly for up to 52 weeks in these pivotal, placebo-controlled trials. Over 2,400 patients have continued into a 72-week open-label extension trial, highlighting the long-term potential of the drug.

LIB Therapeutics is currently preparing a Biologics License Application (BLA) for Lerodalcibep, with plans to submit for regulatory approval in 2024. The company aims to provide new treatment options for patients who require substantial reductions in LDL-C despite the use of maximum tolerated statins and other lipid-lowering agents.

LIB Therapeutics Inc. remains committed to advancing cardiovascular health, focusing on patients with cardiovascular disease and those with familial hypercholesterolemia who need additional LDL-C lowering. The upcoming presentations at the European Atherosclerosis Society Congress represent key milestones in the company’s mission to bring innovative treatments to those in need.